Preoperative Ultra-Short-Course Chemotherapy Combined with Surgery for the Treatment of Chest Wall Tuberculosis

Abstract

Weidong Zhang, Jingfang Chen, Xiaoming Wu, Luyu Chen, Jinxing Wei, Mingqiang Xue, Yuanyuan Liu, Qingzheng Liang Department of Thoracic Surgery, Henan Provincial Chest Hospital, Zhengzhou 450003, Henan Province, People’s Republic of China Correspondence: Weidong Zhang; Qingzheng Liang Email [email protected]; [email protected] Objective: To investigate the safety and efficacy of preoperative ultra-short-course chemotherapy, combined with surgical treatment for chest wall tuberculosis and summarize our experience in this regard, to provide a reference for national and international clinicians. Methods: A retrospective analysis was conducted of the clinical data, preoperative anti-tuberculosis duration, and postoperative recurrence rate in 263 patients with chest wall tuberculosis spanning 5 years. Results: Overall, 263 patients were treated with anti-tuberculosis drugs for about 17.06 ± 12.49 days during the preoperative period. Simple chest wall tuberculosis was treated for 12.82 ± 5.87 days and composite chest wall tuberculosis for 21.04 ± 5.11 days. The postoperative recurrence rate of chest wall tuberculosis was 3.80%, which was close to or lower than the recurrence rate of routine preoperative anti-tuberculous therapy in patients subjected to ultra-short-range anti-tuberculosis treatment before surgery. Conclusion: Preoperative ultra-short-course chemotherapy combined with surgical treatment of chest wall tuberculosis did not increase the recurrence rate of chest wall tuberculosis; moreover, it could effectively shorten hospitalization time and improve patient compliance. Full-line anti-tuberculosis treatment and complete resolution of tuberculosis infections are crucial to curing chest wall tuberculosis. Keywords: chest wall tuberculosis, surgical treatment, ultra-short-course chemotherapy

Keywords

• chest wall tuberculosis
• surgical treatment
• ultra-short-course chemotherapy